Hoe verhoudt CMVL.F's PS Ratio zich tot zijn concurrenten?

CMVL.F is een goede waarde op basis van zijn Price-To-Sales Ratio (10.3x) vergeleken met het gemiddelde van gelijken (25.4x).

Hoe verhoudt CMVL.F's PS Ratio zich tot andere bedrijven in de US Biotechs industrie?

CMVL.F is een goede waarde op basis van de Price-To-Sales -ratio ( 10.3 x) vergeleken met het US Biotechs -industriegemiddelde ( 10 x).

Wat is CMVL.F's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Sales Fair Ratio van { CMVL.F te berekenen voor waarderinganalyse.

Wat is de reële prijs van CMVL.F als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van CMVL.F te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Cellectis (OTCPK:CMVL.F) - Aandelenkoers, Nieuws & Analyse

CMVL.F Overzicht aandelen

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. Meer informatie

CMVL.F fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 39.45% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Cellectis S.A. Concurrenten

Amarin

NasdaqCM:AMRN

US$202.4m

XOMA Royalty

NasdaqGM:XOMA

US$390.8m

Alector

NasdaqGS:ALEC

US$249.2m

Elutia

NasdaqCM:ELUT

US$144.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cellectis
Historische aandelenkoersen
Huidige aandelenkoers	€2.54
52 Week Hoogtepunt	€3.58
52 Week Laag	€0.95
Bèta	3.22
11 maand verandering	0%
3 maanden verandering	-14.19%
1 Jaar Verandering	n/a
33 jaar verandering	-80.46%
5 jaar verandering	-79.45%
Verandering sinds IPO	-45.23%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	CMVL.F	US Biotechs	US Markt
7D	0%	2.4%	0.5%
1Y	n/a	15.6%	30.7%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe CMVL.F presteerde ten opzichte van de US Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe CMVL.F presteerde ten opzichte van de US markt.

Prijsvolatiliteit

Is CMVL.F's price volatile compared to industry and market?
CMVL.F volatility
CMVL.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: CMVL.F heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van CMVL.F in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	219	Andre Choulika	www.cellectis.com

Cellectis S.A. Samenvatting

Hoe verhouden de winst en inkomsten van Cellectis zich tot de beurswaarde?
CMVL.F fundamentele statistieken
Marktkapitalisatie	US$202.13m
Inkomsten(TTM)	-US$78.90m
Inkomsten(TTM)	US$19.64m

10.3x

P/S-verhouding

-2.6x

Koers/Winstverhouding

Is CMVL.F overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CMVL.F resultatenrekening (TTM)
Inkomsten	US$19.64m
Kosten van inkomsten	US$737.00k
Brutowinst	US$18.90m
Overige uitgaven	US$97.80m
Inkomsten	-US$78.90m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.79
Brutomarge	96.25%
Nettowinstmarge	-401.86%
Schuld/Eigen Vermogen Verhouding	28.9%

Hoe presteerde CMVL.F op de lange termijn?

Bekijk historische prestaties en vergelijking

CMVL.F Overzicht aandelen

Beloningen

Risicoanalyse

Cellectis S.A. Concurrenten

NasdaqCM:AMRN

US$202.4m

NasdaqGM:XOMA

US$390.8m

NasdaqGS:ALEC

US$249.2m

NasdaqCM:ELUT

US$144.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Recent updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing and Technologies

Cellectis S.A. Announces Preliminary Results from its Phase 1 Balli-01 Clinical Study of Ucart22 in Adults with R/R B-All Presented in Oral Session At 2020 Ash Annual Meeting

Cellectis S.A. to Report Q4, 2020 Results on Mar 04, 2021

Cytovia Therapeutics, Inc. and Cellectis Enter into Strategic Research and Development Collaboration

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma

Cellectis Appoints Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Cellectis S.A. Appoints Jean-Pierre Garnier, Ph.D as Non-Executive Chairman of the Board of Directors

Cellectis S.A. to Report Q2, 2020 Results on Aug 05, 2020